U-BIOPRED stands for Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes. This is the technical name for the 5-year European-wide project on severe asthma.
The project’s aim is to get a much clearer idea of what severe asthma is, how it differs from person to person, and uncover new information and ideas that could lead to the creation of effective new treatments.
Using scientific and medical information on hundreds of adults and children with severe asthma from around Europe, the project’s scientists hope to identify different sub-types (known as phenotypes) of severe asthma.
Their hope is that detailed ‘handprints’ of severe asthma sub-types will give doctors much-needed information that will help them select the most effective treatment for each patient, and be able to predict the future course of their condition.
In addition, U-BIOPRED researchers will conduct detailed scientific studies to understand severe asthma in greater detail than ever before. This should reveal important molecules that can be targeted to create new treatments for severe asthma.
One of the key strengths of this project is the involvement of pharmaceutical companies, therefore ensuring their interest and commitment and removing many current obstacles that stand in the way of new treatment development.